Hipertensão resistente: problema clínico relevante
Palabras clave:
hipertensão, hipertensão renal, hipertensão maligna, hipertensão renovascularResumen
A hipertensão arterial sistêmica (HAS) pode ser considerada como maior fator de risco independente relacionado à doença cardiovasculares e classificada como um fator de risco modificável, apesar do importante avanço no conhecimento da sua fisiopatologia e disponibilidade de métodos efetivos para o seu tratamento, como o avanço de novos fármacos usados na prática clínica. No Brasil, aproximadamente 37% dos óbitos, quando excluídos óbitos por causas mal definidas e a violência, são relacionados ao aumento de pressão arterial. A HAS aumenta em cinco vezes o risco de acidente vascular encefálico e doença arterial coronariana, quando comparados em adultos normotensos,. A mortalidade aumenta gradativamente a partir de 115/75 mmHg com a elevação das cifras pressóricas. Segundo o JNC VII e o AHA Scientific Statetment for Resistant Hypertension, considera-se paciente portador de HAR, onde após duas consultas consecutivas, os valores pressóricos mantêm-se acima da meta, mesmo com de tratamento não farmacológico e farmacológico tríplice instituído, incluindo-se um diurético.
Descargas
Citas
Aqui está a lista de referências bibliográficas sobre Hipertensão Arterial e Fatores de Risco Cardiovasculares organizada e com as quebras de palavras corrigidas:
Kannel WB. Hypertension as a risk factor for cardiac events--epidemiologic results of long-term studies. J Cardiovasc Pharmacol. 1993; 21(2): S27-37.
Nobre F. VI Brazilian Guidelines in arterial hypertension. Rev hiper. 2010; 13(1).
Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J. 1999; 138(3 Pt 2): 205-10.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349): 1903-13.
Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J. 1999;138(3 Pt 2): 205-10.
Beevers G, Lip GY, O'Brien E. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques. Bmj. 2001a;322(7292):981-5.
Gus I, Harzheim E, Zaslavsky C, Medina C, Gus M. Prevalence, awareness, and control of systemic arterial hypertension in the state of Rio Grande do Sul. Arq Bras Cardiol. 2004;83(5): 429-33; 424-8.
Luft FC. Molecular genetics of human hypertension. J Hypertens. 1998;16(12Pt2): 1871-8.
Ubaid-Girioli S, Ferreira-Melo SE, Souza LA, Nogueira EA, Yugar-Toledo JC, Coca A, et al. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(10): 770-4
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9): 1751-62.
Kaplan NM. Resistant hypertension: what to do after trying 'the usual'. Geriatrics. 1995;50(5): 24-5.
Sarafidis PA, Bakris GL. Resistent Hypertension: An overview of evaluation and treatment. J Am Coll Cardio. 2008;52(22): 1749-57.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 ;117(25): 510-26.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003;289(19): 2560-72.
Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002a;4(3): 221-8.
Kaplan NM. Resistant hypertension. J Hypertens. 2005;23(8): 1441-4.
Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005;11(9): CR403-9.
Almeida F. Hipertensão Arterial Refratária. Programa de Educação Continuada da SBC. 2003; 1(6).
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008a;51(2): 339-44
Messerli FH, Ventura HO, Amodeo C. Osler's maneuver and pseudohypertension. N Engl J Med. 1985 ;312(24): 1548-51.
Zweifler AJ, Shahab ST. Pseudohypertension: a new assessment. J Hypertens. 1993;11(1): 1-6.
Ernst ME, Bergus GR. Noninvasive 24-hour ambulatory blood pressure monitoring: overview of technology and clinical applications. Pharmacotherapy. 2002;22(5): 597-612.
Bane C, Hughes CM, McElnay JC. The impact of depressive symptoms and psychosocial factors on medication adherence in cardiovascular disease. Patient Educ Couns. 2006; 60(2): 187-93.
Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens. 2001;14(7 Pt 2): 231S-236S.
Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3): 345-51.
Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151(9): 1786-92.
Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;12(12): 897-903.
Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep. 2005;7(5): 323-9.
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4): 477-84.
Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. 2003;67(1): 19-24.
Esler MD, Lambert GW, Ferrier C, Kaye DM, Wallin BG, Kalff V, et al. Central nervous system noradrenergic control of sympathetic outflow in normotensive and hypertensive humans. Clin Exp Hypertens. 1995;17(1-2): 409-23.
Bravo EL. Phenylpropanolamine and other over-the-counter vasoactive compounds. Hypertension. 1988;11(3 Pt 2): II7-10.
Cushman WC. Alcohol consumption and hypertension. J Clin Hypertens (Greenwich). 2001;3(3): 166-70.
Britton A, McKee M. The relation between alcohol and cardiovascular disease in Eastern Europe: explaining the paradox. J Epidemiol Community Health. 2000;54(5): 328-32.
Thadhani R, Camargo CAJr, Stampfer MJ, Curhan GC, Willett WC, Rimm EB. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med. 2002;162(5): 569-74.
Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995 ;8(2): 189-92.
Benowitz NL, Hansson A, Jacob P3rd. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension. 2002;39(6): 1107-12.
Moreno HJr, Chalon S, Urae A, Tangphao O, Abiose AK, Hoffman BB, et al. Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. Am J Physiol. 1998;275(3 Pt 2): H1040-5.
Tanus-Santos JE, Toledo JC, Cittadino M, Sabha M, Rocha JC, Moreno HJr. Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers. Am J Hypertens. 2001;14(7 Pt 1): 610-4.
Yugar-Toledo JC, Tanus-Santos JE, Sabha M, Sousa MG, Cittadino M, Tacito LH, et al. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest. 2004;125(3): 823-30.
Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14(6 Pt 1): 491-503.
Haddy FJ. Role of dietary salt in hypertension. Life Sci. 2006 ;79(17): 1585-92.
Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10(5 Pt 2): 49S-55S.
Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14(6 Pt 2): 103S-115S.
Rocchini AP. Obesity hypertension. Am J Hypertens. 2002;15(2 Pt 2):50S-52S.
Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids.1999; 60(5-6):401-5.
Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment. Dis Mon. 1996; 42(10): 609-722.
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002b ;40(6): 892-6.
Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007b;9(1):19-24.
Rayner BL. Screening and diagnosis of primary aldosteronism. Cardiovasc J S Afr. 2002;13(4): 166-70.
Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens. 2008;17(2): 174-80.
Kloner RA, Textor SC, Tavel ME. Renovascular hypertension: problems in evaluation and management. Chest. 2002;121(3): 964-8.
Pimenta E, Gaddam KK, Oparil S, et al. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10(3): 239-44.
Silverberg DS, Oksenberg A, Iaina A. Sleep related breathing disorders are common contributing factors to the production of essential hypertension but are neglected, underdiagnosed, and undertreated. Am J Hypertens. 1997;10(12 Pt 1):1319-25.
Smith ML, Niedermaier ON, Hardy SM, Decker MJ, Strohl KP. Role of hypoxemia in sleep apnea-induced sympathoexcitation. J Auton Nerv Syst. 1996;56(3): 184-90.
Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12): 2271-7.
Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney. 2006;Int 69(6): 967-73
